Effect of mirabegron on cognitive function in elderly patients with overactive bladder: MoCA results from a phase 4 randomized, placebo-controlled study (PILLAR)

• Published in: BMC geriatrics 2020-03, Vol.20 (1), p.109-109, Article 109
• Main Authors: Griebling, Tomas L, Campbell, Noll L, Mangel, Jeffrey, Staskin, David, Herschorn, Sender, Elsouda, Dina, Schermer, Carol R
• Format: Article
• Language: English
• Subjects: Aged; Anticholinergics; Bladder; Clinical trial; Cognition; Cognition & reasoning; Cognitive ability; Cognitive disorders; Comorbidity; Complications and side effects; Dementia; Depression (Mood disorder); Diagnosis; Drug dosages; Drug therapy; Elderly patients; Ethics; Frailty; Geriatrics; Insomnia; Lower urinary tract symptoms; Mental disorders; Mirabegron; Older people; Patients; Phase 4; Psychological aspects; Psychotropic drugs; Risk factors; Time; Urinary bladder; Urinary incontinence
• ISSN: 1471-2318; 1471-2318
• DOI: 10.1186/s12877-020-1474-7

Antimuscarinics are often used for treatment of overactive bladder (OAB), but exposure to medications such as antimuscarinics that have anticholinergic properties has been linked to adverse cognitive effects. A phase 4 placebo-controlled study (PILLAR; NCT02216214) described the efficacy and safety of mirabegron, a β -adrenoreceptor agonist, for treatment of wet OAB in patients aged ≥65 years. This pre-planned analysis aimed to measure differences in cognitive function between mirabegron and placebo, using a rapid screening instrument for mild cognitive impairment: the Montreal Cognitive Assessment (MoCA). Outpatients aged ≥65 years with wet OAB were randomized 1:1 to mirabegron or placebo, stratified by age (